Company

Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Cellectis

Main focus: Next generation allogeneic CAR-T cell therapies

Company stage: Clinical

Diseases: acute myeloid leukaemia, B-cell acute lymphoblastic leukaemia (B-ALL), multiple myeloma, Non-Hodgkin's lymphoma

Genome editing technology: TALEN

Funding stage: Public (NASDAQ:CLLS)

Location: Paris, France and New York, USA

Website: https://www.cellectis.com/en

Pipeline: https://www.cellectis.com/en/products/product-candidates/

Partners: Allogene Therapeutics, Servier Biopharmaceuticals, Iovance Biotherapeutics, Cytovia Therapeutics

Cellectis develops next generation allogeneic CAR-T cell therapies using its proprietary Transcription activator-like effector nuclease (TALEN) technology. The company has multiple clinical assets currently in Phase 1/2 dose escalation and dose expansion studies. The initial focus is on different types of haematological cancers, such as Non-Hodgkin's lymphoma and leukaemia. The company has licensed the TALEN technology to multiple other companies working with cellular therapies.

Tags

HashtagCellectis S.A.

Company: Cellectis
Jobs, banner ads, webinars, sponsored content...
close
Search CRISPR Medicine